Skip to content
Tuesday, January 31, 2023
Latest:
  • When visible meets invisible: the importance of psychological screening and intervention in pediatric dermatology
  • Savor brunch nutritiously
  • Journaling for mental health
  • Ataxia mutant protein uses distinct partners to drive toxicity in different brain cells
  • Recipe: Herb-rubbed Flank Steak

Baylor College of Medicine Blog Network

Baylor College of Medicine Blog Network

  • Home
  • Momentum
    • About Momentum
    • Resources
    • Contributors
      • Dana Benson
      • Molly Chiu
      • Julie Garcia
      • Graciela Gutierrez
      • Anna Kiappes
      • Dipali Pathak
      • Andy Phifer
      • Homa Shalchi
      • Melissa Tucker
    • Contact Us
  • From The Labs
    • About From the Labs
    • Follow From The Labs on Twitter
  • Policywise
    • About PolicyWise
    • Follow @BCMEthics on Twitter
  • The Stitch
    • About The Stitch
  • Progress Notes
    • About Progress Notes
    • Progress Notes Editors
    • Connect With Us
  • bcm.edu

Dr. Christopher Scott

pills
Policywise 

Uncharted waters: Navigating requests for experimental medicines

September 6, 2019September 6, 2019Access, Center for Medical Ethics and Health Policy, Dr. Christopher Scott, Expanded Access Program, Hannah Bablak, investigational drugs, Oncologists, Right-to-Try Act

In May 2018, the federal Right-to-Try Act was signed into law, claiming a new and improved option for patients with no therapeutic options to obtain

Read more
Policywise 

The perils of partnering for profit

November 2, 2018November 1, 2018Big Data, Center for Medical Ethics and Health Policy, conflicts-of-interest, Dr. Christopher Scott, Transparency

Editor’s note: The opinions expressed in the following blog post are the author’s own and do not reflect the views of Baylor College of Medicine.

Read more
Policywise 

The gene therapy watchers: Can an NIH advisory committee reinvent itself?

October 5, 2018October 5, 2018Center for Medical Ethics and Health Policy, Dr. Christopher Scott, FDA, gene therapy, NIH

Francis Collins, NIH Director, and Scott Gottlieb, FDA Commissioner, recently announced plans to eliminate oversight of new gene therapy experiments by the NIH’s Recombinant DNA

Read more
Policywise 

CRISPR: A democratizing technology calls for democratic dialogue

April 27, 2018April 25, 2018CRISPR/Cas9, Deliberative Engagement, DNA, Dr. Christopher Scott, health policy

By now, you may have read stories about a gene editing technique called CRISPR/Cas9. CRISPR is poised to revolutionize the biological sciences because it’s the

Read more
Policywise 

A ‘right to try,’ but at what cost?

April 6, 2018May 2, 2018Center for Medical Ethics and Health Policy, Dr. Christopher Scott, health policy, pharmaceuticals, Right to Try

A few weeks ago, my colleague Stephanie Morain wrote a PolicyWise post on attempts to pass so-called “right-to-try” legislation in the U.S. House of Representatives.

Read more
Policywise 

Life played richly: Learn to live a life of fulfillment

January 11, 2017January 10, 2017Anna Deavere Smith, Center for Medical Ethics and Health Policy, Dr. Christopher Scott, Dr. Jennifer Blumenthal-Barby, ethics

In her critically acclaimed one-person show, Let Me Down Easy, Anna Deavere Smith re-enacts interviews with people observing the rich identity of the human body,

Read more
dna-photo-featured
Policywise 

Gene therapy: An out-of-body experience

July 1, 2016October 7, 2016Affiliates, Center for Medical Ethics and Health Policy, David Vetter, Dr. Christopher Scott, gene therapy, Genetics, Healthcare, Houston, Research

On April 1, 2016, the European Medicines Agency (EMA) approved the first ex-vivo (outside the body) gene therapy in the Western Hemisphere. Diseased stem cells

Read more

From the Labs Image of the Month

From The Labs Image of the Month From the Labs: Adult-born neurons made the cover

Healthy Habits: A DOC-umentary Series

https://www.youtube.com/watch?v=SlNiMWHUhbc

Archives

Search

©1998 - 2020 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951